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After more than 10 years of clinical studies on interleukin (IL)-2
anti-tumour activity, it has been shown that both the activity and
the efficacy of IL-2 cancer immunotherapy on tumour response
and on overall survival, respectively, do not depend upon tumour
characteristics alone, but also on the host’s general status (Palmer
et al, 1993) and immune status (Blay et al, 1992) prior to IL-2
therapy. With regard to pretreatment immune status, some large
studies (Blay et al, 1992; Lopez-Hanninen et al, 1996) have
reported a correlation between high inflammatory activation prior
to the onset of treatment, such as abnormally high pretreatment
values of IL-6, C reactive protein (CRP), or elevated erythro-
sedimentation rate (ESR), and tumour resistance to IL-2 activity.
Neopterin, a specific marker of macrophage activation,
(Diamondstone et al, 1994) and circulating levels of soluble IL-2
receptor (sIL-2R), whose main source would be T-cells (Rubin et
al, 1985), could be two other important parameters of the inflam-
matory response activation and may, in fact, suggest the involve-
ment of both macrophages and lymphocytes in the
physiopathology of cancer-induced immune unbalance.
So far, most studies have evaluated the prognostic significance
of a single immune index on IL-2 immunotherapy (Jeal and Goa,
1997). Therefore, the physiopathology of mechanisms responsible
for the prognostic significance of baseline levels of a single
cytokine, or of other immune markers after exogenous IL-2 admin-
istration, have still to be thoroughly investigated and established.
Among possible mechanisms, the documented inhibitory effect of
IL-6 on IL-2-induced generation of cytotoxic lymphocytes
(Kishimoto, 1989) may be responsible for tumour resistance to
IL-2 therapy in patients with high levels of endogenous IL-6. In
contrast, the lack of IL-2 anti-tumour activity in the presence of
pretreatment elevated blood levels of neopterin (Lissoni et al, 1994)
and/or sIL-2R (Gooding et al, 1995) is more difficult to explain, as
the increased levels of neopterin and sIL-2R reflect the activation
of the immune system in either an anti-tumour or an immuno-
suppressive way (Rubin et al, 1985; Diamondstone et al, 1994;
Jeal and Goa, 1997). At present, it is still unclear whether the
association among high pretreatment circulating IL-6, neopterin
and sIL-2R, and resistance to IL-2 anti-tumour activity may reflect
different unrelated cytokine alterations or, on the contrary, whether
the association may outline a common pathway responsible for the
deficiency of the anti-tumour immune activation.
With regard to host response after IL-2 administration, it is
known that lymphocytes play a fundamental role in mediating
tumour cell destruction (Grimm et al, 1982) and that rebound
lymphocytosis represents the typical biomarker of immune
activation in response to IL-2 injection (Palmer et al, 1993).
Furthermore, in patients with metastatic renal cell cancer who
achieve an objective response, a higher lymphocyte increase has
been observed after IL-2 subcutaneous (s.c.) therapy (Gohring
et al, 1996). On this basis, the present study was carried out to
evaluate host response after IL-2 s.c. low-dose immunotherapy in
metastatic cancer patients, measured as post-treatment changes in
lymphocyte number, in relation to the pretreatment values of IL-6,
neopterin, sIL-2R and ESR.
PATIENTS AND METHODS
From January to October 1996, 20 consecutive metastatic renal
cell cancer (RCC) patients entered the study. The characteristics of
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Summary Lymphocytosis is a marker of subcutaneous interleukin (IL)-2 therapy efficacy, whereas baseline elevated inflammatory indices
were noticed in IL-2-resistant disease. The aim of this study was to analyse the relationship between pretreatment circulating values of IL-6,
neopterin, sIL-2R, ESR and the changes in lymphocyte number in response to IL-2 administration. Twenty metastatic renal cell cancer
patients were treated with subcutaneous IL-2 immunotherapy (6 000 000 IU day–1 for 6 days per week for 4 weeks); tumour response
consisted of partial response (PR) in four patients, stable disease (SD) in eight patients and progressive disease (PD) in eight patients.
Abnormally high pretreatment values of each marker were found as follows: IL-6 in seven patients, neopterin in nine patients, sIL-2R in 13
patients. In response to IL-2 immunotherapy, a significantly higher mean increase in lymphocyte number and a higher percentage of patients
with tumour response or stable disease were observed when pretreatment values of IL-6, neopterin and sIL-2R were within the normal range,
in comparison to patients with high values for these markers. The pretreatment excess of these serum inflammatory markers seems to
negatively influence both the host and tumour response to IL-2 administration, by preventing the IL-2-induced lymphocytosis and resulting in
tumour progression. Further studies are requested to verify if overall survival and quality of life may depend on pretreatment host immune
status and/or lymphocyte response after IL-2 administration.
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Correspondence to: P Lissonipatients are reported in Table 1. Eligibility criteria were: hysto-
logically proven metastatic renal cell cancer, measurable disease,
first-line therapy of the metastatic stage, previous nephrectomy,
age less than 80 years, a performance status (PS) according to
Karnofsky score greater than 70%, no concomitant chronic
therapy with steroids or other drugs influencing the immune
system, no important illnesses other than cancer, no brain
metastasis and no second tumour.
Recombinant human IL-2 was injected s.c. at a dose of
3 000 000 IU twice daily for 6 days per week for 4 consecutive
weeks, corresponding to one complete immunotherapeutic cycle.
The clinical response was evaluated according to WHO criteria. In
non-progressing patients, a second cycle was administered after a 21-
day rest. Following this, patients underwent a maintenance schedule
consisting of treatment 6 days per month, until progression or
toxicity. Routine laboratory tests, including differential count, were
performed before the onset of IL-2 treatment and at 1-week intervals
until the end of the cycle. Venous blood samples were collected the
morning before the onset of therapy. Serum levels of IL-6 and sIL-2R
were measured by an enzyme immunoassay using commercially
available kits. Intra-assay and interassay coefficients of variation,
established by at least 20 consecutive assays, were less than 5% and
7% for IL-6 and less than 5% and 6% for sIL-2R respectively. Serum
levels of neopterin were measured by radioimmunoassay using
commercially available kits. Intra-assay and interassay coefficients
of variation were less than 4% and 5% respectively. Normal values
obtained in our laboratory (95% confidence limits) in 20 healthy
subjects were as follows: IL-6 < 31 pg ml–1; neopterin < 2.5 ng ml–1;
sIL-2R < 920 U ml–1; ESR < 20 mm per hour; lymphocyte count
> 1000 mmc. Results were reported as the mean ± s.e.m. Changes
in lymphocyte mean number were expressed as mean maximum
increase observed during the first immunotherapeutic cycle. Data
were statistically analysed by the c2 test, Student’s t-test and analysis
of variance, as appropriate.
RESULTS
Tumour objective response consisted of partial remission (PR) in
4/20 patients (20%), with a median duration of 8+ months (range:
4–11+ months). Stable disease (SD) was observed in 8/20 (40%)
patients, whereas the remaining eight patients showed progressive
disease (PD) in response to the first immunotherapeutic cycle.
The following immunoinflammatory serum markers were found
to be at abnormally high pretreatment levels respectively: IL-6
in 7/20 (35%) patients, neopterin in 9/20 (45%) patients and
sIL-2R in 13/20 (65%) patients. ESR baseline values greater than
40 mm h–1 were observed in 14/20 (70%) patients.
Mean increase in lymphocyte number occurring in patients
during IL-2 administration, in relation to the pretreatment values
of IL-6, neopterin, sIL-2R and ESR are shown in Table 2. The
mean increase in lymphocyte number shown by patients having
normal pretreatment values of IL-6, neopterin and sIL-2R was
significantly higher than that observed in patients having elevated
values of the same markers. For ESR, the lymphocyte increase in
patients with a baseline value < 40 mm h–1 was higher than in
patients having a baseline value > 40 mm h–1, but not significantly.
The relationship of pretreatment values of IL-6 to neopterin and
sIL-2R levels is shown in Table 3. It is noted that IL-6 mean serum
values were significantly higher in patients having previously
elevated neopterin values vs normal, as well as in patients with
high sIL-2R concentrations vs normal.
Regarding objective tumour response, a higher percentage of
patients having elevated baseline values of the immunoinflamma-
tory markers (respectively IL-6, neopterin, sIL-2R and ESR)
showed tumour progression, whereas patients having baseline
values within normal range for the same markers showed a higher
rate of non-progressing disease (PR ± SD). Details are shown in
Table 4.
DISCUSSION
Elevated values of a specific inflammatory markers, such as CRP
and ESR, are frequent in advanced cancer patients with poor
prognostic characteristics, such as cachexia (Scott et al, 1996).
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Table 1 Clinical characteristics of metastatic renal cell cancer patients
n 20
M/F 12/8
Median age (years) 59 (45–76)
Median PS (Karnofsky %) 90 (80–100)
Dominant metastatic sites
Lung 12
Bone 5
Liver 3
Table 2 Mean increase in total lymphocyte number in relation to the
pretreatment values of IL-6, neopterin, sIL-2R and ESR
Pretreatment marker 
Lymphocyte increase during IL-2
value no. of patients (n-mmc) P
IL-6
High 7/20 678 ± 82
Normal 13/20 2543 ± 121 < 0.001
Neopterin
High 9/20 1132 ± 237
Normal 11/20 2369 ± 214 < 0.025
sIL-2R
High 13/20 1332 ± 169
Normal 7/20 2458 ± 342 < 0.05
ESR
> 40 mm h–1 14/20 1456 ± 353
< 40 mm h–1 6/20 2013 ± 195 NS
NS, not significant.
Table 3 Pretreatment IL-6 serum values in relation to neopterin and sIL-2R
values
Baseline marker value IL-6 value
(pg ml–1) P
Neopterin
High 94 ± 19
Normal 34 ± 8 < 0.05
sIL-2R
High 89 ± 21
Normal 17 ± 3 < 0.025Moreover, it is already known that lymphocytopenia (Stanley,
1980) and/or low lymphocyte percentage (Maltoni et al, 1997)
are independent predictive factors for short survival in cancer
patients, whereas a higher lymphocyte number is related to longer
survival (Riesco, 1970; Kim et al, 1976; Stanley, 1980). Until
recently, the underlying mechanisms responsible for the debilita-
tion of the host immune status could not be explained. Recent
advances in understanding the biology of the tumour in relation
to the host (Yoshino et al, 1992) demonstrate that this immune
imbalance can in part be explained by the decreased production of
endogenous IL-2 (Monson et al, 1986; Lissoni et al, 1989).
Further, enhanced production of a number of agents, including IL-
6 itself, IL-10 (Koo et al, 1992; Gastl et al, 1993), prostaglandin
E2 (Chouaib and Fradelizi, 1982) and (TGF-b) may exert either a
suppressive or pro-inflammatory activity, resulting in inhibition
of IL-2-induced anti-tumour activity (Sedlmayr et al, 1991;
Fischer et al, 1995).
Previous large scale studies on IL-2 treatment have shown that
pretreatment high inflammatory activation, measured by markers
such as IL-6 and CRP, predicts lack of IL-2 activity on tumour
objective response and its efficacy on overall survival in metastatic
cancer patients (Blay et al, 1992; Tartour et al, 1994). However, a
separate, smaller study demonstrated that detectable IL-6 serum
levels correlated with paraneoplastic syndromes but not with
response or survival (Walther et al, 1998). Regarding lymphocyte
count changes, some studies (Palmer et al, 1993; Gohring et al,
1996) demonstrated that a greater lymphocyte increase after s.c.
IL-2 administration occurrs in metastatic renal cell cancer patients
with objective response. According to preliminary data, a greater
lymphocyte increase is observed in patients with peak of
endogenous IL-12 serum levels ³ 100% vs baseline after s.c.
IL-2 administration (Lissoni et al, 1998).
The results of our study confirm that pretreatment inflammatory
activation, measured as circulating abnormal levels of IL-6,
neopterin and sIL-2R, negatively influences the host response to
IL-2 administration, represented by the lack of rebound lympho-
cytosis. Moreover, IL-6 values are higher in patients who show
previously elevated blood levels of neopterin and/or sIL-2R.
The involvement of dominant metastasis site in influencing the
host response could not be assessed in this study, as the number of
patients within each dominant metastasis category were too low to
make any correlation between metastasis site and serum markers.
Indeed, further larger studies will be required to establish whether
the increase in lymphocyte number in relation to the clinical
response may be influenced by the site of disease.
The findings of this study may be considered with regard to both
the biological and the clinical aspects of the immune physio-
pathology of cancer. Immunobiologically, these observations
suggest that the inflammatory activation in metastatic cancer is
likely to be multifactorial, involving at least both macrophages and
lymphocytes, as indicated by neopterin and sIL-2R respectively.
Secondarily, the inflammatory pathway activation may influence
the function of the whole lymphatic compartment, as represented
by unpaired lymphocyte growth (and/or lymphocyte recirculation)
after stimulation with IL-2.
The high levels of circulating sIL-2R and IL-6 would directly
inhibit the physiologic IL-2-dependent immune cell response as
demonstrated both in vitro and in vivo. The circulating sIL-2R
would act by the binding of circulating IL-2 (Rubin et al, 1986)
and abrogating the activation of peripheral mononuclear cells
(Zorn et al, 1994; Gooding et al, 1995), whereas IL-6 is able to
inhibit both the natural killer activity (Tanner and Tosato, 1991)
and the lymphokine-activated killer cell activity (Scheid et al,
1994). Finally, IL-6 may act as autocrine tumour growth factor in
renal cell carcinoma (Koo et al, 1992).
The negative effect of the macrophage marker neopterin
(Diamondstone et al, 1994) on IL-2-dependent immune function
might be related to the suppressive activity exerted by
macrophages in malignancy (Naor and Duke Cohan, 1986), as we
are not aware of direct influence of neopterin on IL-2 activity.
Indeed, high pretreatment values of neopterin may reflect a patho-
logically unfavourable activity of macrophages in cancer, possibly
exerted through other mediators; in agreement with this hypoth-
esis, the poor prognostic value of high serum levels of macrophage
colony-stimulating factor (M-CSF) in patients with lung cancer
was recently described (Katsumata et al, 1996).
Regarding clinical aspects, the present study suggests that
elevated pretreatment inflammatory status negatively influences
not only the biological effects, but also the therapeutic activity
exerted by IL-2 on both the host and the tumour, represented by the
impairment of lymphocyte rebound and by tumour progression
following IL-2 administration respectively.
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Table 4 Tumour objective response in relation to normal or elevated pretreatment values of IL-6, neopterin, sIL-2R and ESR in 20 metastatic renal cell cancer
patients
Marker
Tumour response (n)
Pretreatment value no. of patients CR PR SD PD OR ± SD (%) P
IL-6
High 7 – – 2 5 2/7 (29)
Normal 13 – 4 6 3 10/13 (77) < 0.01
Neopterin
High 9 – 1 2 6 3/9 (33)
Normal 11 – 3 6 2 9/11 (82) < 0.05
sIL-2R
High 13 – 2 4 7 6/13 (46)
Normal 7 – 2 4 1 6/7 (86) < 0.05
ESR
> 40 mm h–1 14 – 1 6 7 7/14 (50)
≤ 40 mm h–1 6 – 3 2 1 5/6 (83) < 0.05Unlike studies involving chemotherapeutic drugs in which only
objective tumour regression is considered because only tumour
destruction – mainly complete response – following antiblastic
agents administration is generally associated with improvement of
survival and quality of life, in our study the tumour response and
the stable disease were considered together as therapeutic effects
of IL-2 treatment. In fact, unlike chemotherapeutic agents, IL-2
acts to boost the host defense system and provides clinical benefit
in overall survival (patient outcome) not only following tumour
disappearance, but also in patients achieving stable disease, whose
overall and median survival is in fact reported to be equal to those
of partial responders (Schoof et al, 1993; Buzio et al, 1997; Figlin
et al, 1997).
The possibility to predict the host response to cytokine
treatment might play an important role in the clinical planning of
treatments. In fact, the characterization of the pretreatment inflam-
matory status would influence the choice of patients suitable for
IL-2 therapy, or would identify the most appropriate time to start
IL-2 treatment, e.g. only after effective suppression of the inflam-
matory pathways.
Indeed, the identification of biomarkers other than the tumour
response able to predict the patient survival (American Society of
Clinical Oncology, 1996) would allow the design of therapeutic
strategies using appropriate cytokine administration. This would
verify if the therapeutic rebalance of the host immune system
(Wojtowicz-Praga, 1997) may improve patient outcome in cancer.
The results of previous, and the present, studies suggest that both
pretreatment inflammatory markers – such as IL-6, neopterin and
sIL-2R – and the host response after IL-2 administration (i.e.
lymphocytosis) are worth further studies as to their value as poten-
tial biomarkers for cancer treatment major end points, that is
overall survival and quality of life, in an appropriate number of
patients.
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